Strategies for vaccine development of COVID-19.
- Author:
Limin YANG
1
;
Deyu TIAN
1
;
Wenjun LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: COVID-19; antibody; antibody-dependent enhancement; mucosal immunization; vaccine
- MeSH: Betacoronavirus; immunology; Biomedical Research; Coronavirus Infections; epidemiology; immunology; prevention & control; virology; Humans; Internationality; Middle East Respiratory Syndrome Coronavirus; immunology; Pandemics; prevention & control; Pneumonia, Viral; epidemiology; immunology; prevention & control; virology; SARS Virus; immunology; Severe Acute Respiratory Syndrome; immunology; Viral Vaccines; immunology
- From:Chinese Journal of Biotechnology 2020;36(4):593-604
- CountryChina
- Language:Chinese
- Abstract: An epidemic of acute respiratory syndrome in humans, which appeared in Wuhan, China in December 2019, was caused by a novel coronavirus (SARS-CoV-2). This disease was named as "Coronavirus Disease 2019" (COVID-19). SARS-CoV-2 was first identified as an etiological pathogen of COVID-19, belonging to the species of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV). The speed of both the geographical transmission and the sudden increase in numbers of cases is much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus, which outbreaks in 211 countries/territories/areas. The vaccine against COVID-19, regarded as an effective prophylactic strategy for control and prevention, is being developed in about 90 institutions worldwide. The experiences and lessons encountered in the previous SARS and MERS vaccine research can be used for reference in the development of COVID-19 vaccine. The present paper hopes to provide some insights for COVID-19 vaccines researchers.
